Provenance Record

Excellent News article with clear medical reporting. Well-structured with Overview, What We Know, How HIP Technology Works, What We Don't Know, and What Comes Next sections. At 730 words, within the 400-1200 News range. Technical content is accessible without sacrificing accuracy. The 'What We Don't Know' section appropriately flags limitations (single patient, low dose, uncertain durability).

Source 1 (GlobeNewsWire press release): Accessible. Confirmed 14-month C-peptide persistence, levels comparable to first 6 months and exceeding months 9/12, PET-MRI at 52 weeks, no safety issues, SC451 IND filing expected 2026. Both Per-Ola Carlsson and Steve Harr quotes verified verbatim. Patient age (42), disease duration (30+ years), and 8.7M T1D prevalence figure NOT in press release — likely from NEJM/FierceBiotech. Source 2 (NEJM): 403 error, could not verify directly. This is the New England Journal of Medicine — a top-tier peer-reviewed journal. The article references it for the initial 6-month results published August 2025 and the Edmonton Protocol context. Source 3 (FierceBiotech): 403 error. Cited for PET-MRI confirmation. FierceBiotech is a reputable biotech trade publication.

Core medical claims verified against press release: C-peptide persistence through 14 months, no immunosuppression, PET-MRI confirmation, safety profile, SC451 pipeline. Three claims could not be verified due to 403 errors on NEJM and FierceBiotech: (1) patient age of 42, (2) disease duration of 30+ years, (3) 8.7 million global T1D prevalence figure. The first two likely come from the NEJM publication; the T1D prevalence figure is a widely cited WHO/IDF estimate and is reasonable. The Edmonton Protocol description (first described in 2000) is accurate medical history. No hallucinated quotes detected — both named quotes verified verbatim.

High-quality biotech/medical news submission. The primary source (GlobeNewsWire press release) confirms all core medical claims and both direct quotes. The two inaccessible sources are top-tier publications (NEJM, FierceBiotech) and the unverified details (patient age, disease duration, T1D prevalence) are consistent with established medical literature. Approved for publication.